View Post

SWOG’s 1501 study takes aim at the silo wall between cardiology and oncology

In Clinical Trials by Barbara Jacoby

By: Justin Floyd From: cancerletter.com Many have written and spoken about the goal of eliminating the effect of developing and delivering medical care in “silos.” Silos can simply be defined as medical or scientific environments functioning in parallel. They are independent and not often visible by those working in another silo. Silos often exist unintentionally, but have been a real …

View Post

Strategies developed to include more racial and ethnic minorities in clinical trials

In Clinical Trials by Barbara Jacoby

Source: Medical University of South Carolina From: eurekalert.org Not one size fits all, and nowhere does that show up more than in the recruitment of racial and ethnic minorities into clinical trials, says Hollings Cancer Center researcher Marvella Ford, Ph.D. This is critically important since this population has a high prevalence of certain cancers. Ford, who is associate director of …

View Post

New ORNL AI tool revolutionizes process for matching cancer patients with clinical trials

In Clinical Trials by Barbara Jacoby

Source: DOE/Oak Ridge National Laboratory From: eurekalert.org A team of researchers from the Department of Energy’s Oak Ridge National Laboratory Health Data Sciences Institute have harnessed the power of artificial intelligence to better match cancer patients with clinical trials. The researchers were one of ten teams to develop a digital tool to address complex challenges relevant to medical conditions such …

View Post

NKMax America Announces FDA Approval of IND for Phase 1 Trial of SNK01 in Patients with Refractory Cancer

In Clinical Trials by Barbara Jacoby

Source: NKMax America, Inc. From: prnewswire.com NKMax America, a biotechnology company harnessing the power of the body’s immune system through the development of Natural Killer (NK) cell therapies, announced today that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for SNK01, an autologous NK cell adoptive immunotherapy candidate for the treatment of patients …

View Post

Patient-reported symptoms offer insight for clinical trials

In Clinical Trials by Barbara Jacoby

By: University of North Carolina at Chapel Hill School of Medicine From: medicalxpress.com University of North Carolina Lineberger Comprehensive Cancer Center researchers and collaborators found that allowing patients to write, in their own words, about treatment-related symptoms they experienced while participating in clinical trials can provide valuable information. In a first-of-its-kind study published in the Journal of the American Medical …

View Post

Structural and clinical barriers keep 3 of 4 cancer patients from participating in trials

In Clinical Trials by Barbara Jacoby

By: Diane Mapes From: fredhutch.org A new meta-analysis led by Dr. Joseph Unger of Fred Hutchinson Cancer Research Center has revealed that structural and clinical barriers prevent more than 3 out of 4 cancer patients from participating in clinical trials. The study is part of an ongoing effort to understand why patient participation is so low in cancer clinical trials. …

View Post

Enrollment Complete in Phase 2 Trial of NeuVax-Herceptin for HER2-Positive, High-Risk Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Alice Melão From: breastcancer-news.com The investigator-sponsored trial studying a combination of NeuVax (nelipepimut-S, NPS) and Herceptin (trastuzumab) as a maintenance treatment for HER2-positive breast cancer at high risk of recurrence has completed patient enrollment, Sellas Life Sciences, NeuVax’s developer, has announced. Top-line data from the trial is expected by the end of 2019. “The completion of enrollment of this Phase 2 clinical …

View Post

How Social Media Can Advance Cancer Research

In Clinical Trials by Barbara Jacoby

By: Dr. Miriam A Knoll, M.D. From: forbes.com Cancer kills more people in the United States than accidents, stroke, Alzheimer’s and diabetes combined. In 2017, despite spending 147 billion U.S. healthcare dollars on cancer care, 600,000 people died from cancer and 1.7 million new people were diagnosed with cancer. But the news is not all grim: in all, 2.6 million lives were …

View Post

Oncoceutics Expands Patent Family to Include Use of ONC201 in H3 K27M-Mutant Gliomas

In Clinical Trials by Barbara Jacoby

Oncoceutics, Inc. announced that the United States Patent and Trademark Office (USPTO) has issued patent #10,172,862 for the use of ONC201 to treat midline gliomas having a Histone 3 K27M (H3 K27M) mutation. This patent extends the ONC201 patent life through at least 2038. This patent is the eighth issued on ONC201 in the United States, and expands the IP …

View Post

The Pain Clinic – Solving the five most common problems in clinical trials

In Clinical Trials by Barbara Jacoby

At Partnerships in Clinical Trials in Barcelona (Nov 2018), Kate O’Brien, formally a senior research nurse and now a site consultant, led a problem solving forum for all aspects of running clinical trials. Here she examines the most common problems and the potential solutions to them. The concept behind this initiative was to identify some of the issues that face different areas of …